ClinicalTrials.gg
Active, not recruitingNCT06804993Updated Feb 3, 2025

Rectocele Repair with or Without Internal Sphincter Botulinum Toxin Injection: a Prospective Randomized Trial

A Phase 4 interventional study of Transvaginal repair & botulinum toxin type A injection and Transvaginal repair & distilled water injection in Obstructed Defaecation Syndrome and Anterior Rectocele, sponsored by Mansoura University. Active, not recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Mansoura University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 5 months after the study started (first participant enrolled Jul 2021, registered Jan 2025).
Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

This is a single-centre, prospective randomized controlled trial on female patients with anterior rectocele associated with obstructed defecation syndrome

02

Conditions studied

  • Obstructed Defaecation Syndrome
  • Anterior Rectocele

Browse trials for

03

In context

Rectocele

50 studies on the registry are indexed under Rectocele; 9 are open to participants now.

This study's planned enrollment of 60 is close to the median of 62 across 37 interventional studies indexed under Rectocele.

Browse Rectocele studies →

Lead sponsor

Mansoura University is the lead sponsor of 1,119 studies on the registry; 183 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: all required

  • female patients
  • symptomatic rectocele
  • failed conservative treatments for at least 3 months
  • anterior rectocele larger than 3 cm in size in defecogram.
  • retention of the contrast in the rectocele on defecography
  • obstructed defecation manifestations: excessive straining, a sense of incomplete evacuation, the need for digital manipulation during defecation, or dyspareunia

Exclusion Criteria:

  • significant urinary manifestations due to anterior vaginal wall prolapse
  • recurrent rectocele
  • previous anal surgery
  • slow-transit constipation
  • faecal incontinence (FI)
  • abnormal thyroid functions
  • patients under systemic treatment
  • patients with connective tissue disease
  • >3
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Transvaginal repair & botulinum toxin type A toxin injection

    Drug: Transvaginal repair & botulinum toxin type A injection

  • Placebo comparator
    Transvaginal repair & distilled water injection

    Procedure: Transvaginal repair & distilled water injection

Interventions

  • DrugTransvaginal repair & botulinum toxin type A injection

    100 units of lyophilized botulinum toxin type A were diluted in saline to 50 U/mL before the injections. A total of 30 units of type-A botulinum toxin was injected with a 22-G needle evenly divided in 3 sites, 2 on either side of the internal anal sphincter (3 and 9 O'clock) and the third anteriorly (at 12 O'clock)

  • ProcedureTransvaginal repair & distilled water injection

    A total of 30 units of distilled water was injected with a 22-G needle evenly divided into 3 sites, 2 on either side of the internal anal sphincter (3 and 9 O'clock) and the third anteriorly (at 12 O'clock)

06

What researchers measure

Primary outcomes

  1. Recurrence rate

    Time frame: One year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06804993
Responsible party
Mostafa shalaby, MD, MSc, PhD (Associate Professor & Consultant Colorectal Surgeon, Mansoura University) — Principal investigator
First posted
Feb 3, 2025
Start date
Jul 31, 2021
Primary completion
Sep 30, 2023
Completion
Mar 31, 2025 (estimated)
Last update
Feb 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion